These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15959777)

  • 1. Successful outcome with anagrelide in pregnancy.
    Alkindi S; Dennison D; Pathare A
    Ann Hematol; 2005 Oct; 84(11):758-9. PubMed ID: 15959777
    [No Abstract]   [Full Text] [Related]  

  • 2. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful pregnancies after recurrent abortions in mild essential thrombocythemia.
    Kaaja RJ; Leinonen PJ
    Acta Obstet Gynecol Scand; 1998 Nov; 77(10):1022-3. PubMed ID: 9849849
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombocytosis--report of a case.
    Thomas M; Pavithran K; Salil ; Somarajan A
    J Assoc Physicians India; 2000 Apr; 48(4):441-2. PubMed ID: 11273186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of anagrelide in the treatment of thrombocytosis.
    Brooks WG; Stanley DD; Goode JV
    Ann Pharmacother; 1999 Oct; 33(10):1116-8, 1121. PubMed ID: 10534225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of essential thrombocythemia with anagrelide in a child.
    Hermann J; Fuchs D; Sauerbrey A; Hempel L; Zintl F
    Med Pediatr Oncol; 1998 Jun; 30(6):367-70; discussion 370-1. PubMed ID: 9589087
    [No Abstract]   [Full Text] [Related]  

  • 7. Is anagrelide safe during pregnancy?
    Cornet N; Vialard F; Mir O; Berveiller P
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):697-699. PubMed ID: 28866127
    [No Abstract]   [Full Text] [Related]  

  • 8. Anagrelide for essential thrombocythemia.
    Med Lett Drugs Ther; 1997 Dec; 39(1016):120. PubMed ID: 9422046
    [No Abstract]   [Full Text] [Related]  

  • 9. Anagrelide: 20 years later.
    Emadi A; Spivak JL
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
    Bennett M
    Harefuah; 1999 May; 136(9):717-20. PubMed ID: 10955097
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.
    Chen YG; Lin CS; Shen CH; Chian CF
    Jpn J Clin Oncol; 2012 Aug; 42(8):761-3. PubMed ID: 22689919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
    Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: successful pregnancy and delivery after myocardial infarction and essential thrombocythemia treated with clopidrogel.
    Klinzing P; Markert UR; Liesaus K; Peiker G
    Clin Exp Obstet Gynecol; 2001; 28(4):215-6. PubMed ID: 11838740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocytosis.
    Cheung MC; Hicks LK; Pendergrast J
    N Engl J Med; 2004 Jun; 350(24):2524-5; author reply 2524-5. PubMed ID: 15190151
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
    Penninga E; Jensen BA; Hansen PB; Clausen NT; Mourits-Andersen T; Nielsen OJ; Hasselbalch HC
    Clin Lab Haematol; 2004 Oct; 26(5):335-40. PubMed ID: 15485463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.